Abstract: Remarkable upregulation of the NRF2 (NFE2L2)-related transcription factor NRF3 (NFE2L3) in several cancer tissues and its correlation with poor prognosis strongly suggest the physiological function of NRF3 in tumors. Indeed, we had recently uncovered the function of NRF3, which promotes cancer cell proliferation by p53 degradation via the 20S proteasome. Nevertheless, the molecular mechanism underlying the induction of NRF3 gene expression in cancer cells is highly elusive. We herein describe that NRF3 upregulation is induced by the β-catenin/TCF4 complex in colon cancer cells. We first confirmed high NRF3 mRNA expression in human colon cancer specimens. The genome database indicated that the human NRF3 gene possesses a species-conserved WRE sequence (TCF/LEF consensus element), implying that the β-catenin/TCF complex activates NRF3 expression in colon cancer. Consistently, we observed that the β-catenin/TCF4 complex mediates NRF3 expression by binding directly to the WRE site. Furthermore, inducing NRF3 activates cell proliferation and the expression of the glucose transporter GLUT1. The existence of the β-catenin/TCF4-NRF3 axis was also validated in the intestine and organoids of Apc-deficient mice. Finally, the positive correlation between NRF3 and β-catenin target gene expression strongly supports our conclusion. Our findings clearly demonstrate that NRF3 induction in cancer cells is controlled by the Wnt/β-catenin pathway.
Introduction
The development of human cancer genome databases such as The Cancer Genome Atlas (TCGA) and Oncomine have led directly to the discovery of significant functional mutations in genes and pathways [1, 2] . This information also indicates that the biological roles and regulatory mechanisms of numerous genes in tumorigenesis are not defined. Thus, determining these unknown roles will be indispensable for the development of promising targeted molecules for new cancer therapies and precision medicine.
Results

High Expression of The NRF3 Gene in Human Colorectal Cancer Specimens
To further examine the biological relevance of NRF3 in cancer, we first conducted an NRF3 expression analysis using a human cancer RNA dot blot (Figure 1 ). The blot possesses RNA derived from both tumor (T) and adjacent normal (N) tissues for various human cancers. Intriguingly, NRF3 mRNA expression was induced in several types of cancer, especially in colon and rectal carcinoma. These results strengthen our hypothesis that NRF3 is involved in colorectal carcinogenesis.
from both tumor (T) and adjacent normal (N) tissues for various human cancers. Intriguingly, NRF3 mRNA expression was induced in several types of cancer, especially in colon and rectal carcinoma. These results strengthen our hypothesis that NRF3 is involved in colorectal carcinogenesis. The bar graph shows the quantified signal intensity of each dot. The data are presented as the mean ± SD. n, patient number. * p < 0.05, *** p < 0.005 (t-test). n.s., not significant.
The β-catenin/TCF4 Complex Directly Mediates NRF3 Gene Induction in Cancer Cells
To investigate the molecular mechanism underlying NRF3 gene induction in colorectal cancer cells, we considered possible regulation by the β-catenin/TCF complex. Mutations in the Wnt-β-catenin pathway are crucial initial events in colon carcinogenesis [18] [19] [20] . We searched the regulatory region of the NRF3 gene and successfully found a species-conserved WRE sequence as the TCF recognition element in its first intron ( Figure 2A ). The bar graph shows the quantified signal intensity of each dot. The data are presented as the mean ± SD. n, patient number. * p < 0.05, *** p < 0.005 (t-test). n.s., not significant.
To investigate the molecular mechanism underlying NRF3 gene induction in colorectal cancer cells, we considered possible regulation by the β-catenin/TCF complex. Mutations in the Wnt-β-catenin pathway are crucial initial events in colon carcinogenesis [18] [19] [20] . We searched the regulatory region of the NRF3 gene and successfully found a species-conserved WRE sequence as the TCF recognition element in its first intron (Figure 2A ). expression at both the mRNA (D, F) and protein levels (E, G). Two independent siRNAs against the indicated genes were transfected into HCT116 cells, and qRT-PCR and western blot analyses were performed 48 h after transfection. The arrows and arrowheads in the immunoblots indicate the cytoplasmic and nuclear forms of NRF3, respectively. An immunoblot using an anti-TCF4 antibody showed two splicing variants of the TCF4 protein (G). (H) The β-catenin/TCF4 complex inhibitor iCRT14 also suppressed NRF3 mRNA expression in HCT116 cells. mRNA and protein expression were normalized to β-actin mRNA and α-Tubulin protein expression, respectively. The data are presented as the mean ± SD (n = 3). * p < 0.05, *** p < 0.005 (t-test in C and H, ANOVA/Tukey in D-G). (D-G) Knockdown of β-catenin (D, E) or TCF4 (F, G) significantly reduced NRF3 expression at both the mRNA (D, F) and protein levels (E, G). Two independent siRNAs against the indicated genes were transfected into HCT116 cells, and qRT-PCR and western blot analyses were performed 48 h after transfection. The arrows and arrowheads in the immunoblots indicate the cytoplasmic and nuclear forms of NRF3, respectively. An immunoblot using an anti-TCF4 antibody showed two splicing variants of the TCF4 protein (G). (H) The β-catenin/TCF4 complex inhibitor iCRT14 also suppressed NRF3 mRNA expression in HCT116 cells. mRNA and protein expression were normalized to β-actin mRNA and α-Tubulin protein expression, respectively. The data are presented as the mean ± SD (n = 3). * p < 0.05, *** p < 0.005 (t-test in C and H, ANOVA/Tukey in D-G).
To further confirm our hypothesis, we explored whether β-catenin/TCF binds directly to the WRE sequence in the NRF3 gene. In the TCF/LEF family, TCF4 was reported to be abundantly expressed in colon cancer cells [19, 26] . Supporting this notion, we observed that TCF4 mRNA levels were much higher than LEF1 mRNA levels in HCT116 cells ( Figure 2B ), implying that TCF4 could be a regulator of NRF3 gene expression. We next carried out a chromatin immunoprecipitation analysis to assess the direct binding of both β-catenin and TCF4 to the WRE sequence ( Figure 2C ). As expected, the data clearly demonstrated the recruitment of β-catenin/TCF4 to the NRF3 gene.
We addressed the question of whether the β-catenin/TCF4 complex mediates NRF3 expression ( Figure 2D-G) . For this purpose, we used two different approaches. First, we examined the effects of β-catenin or TCF4 knockdown on NRF3 expression in HCT116 cells. siRNAs against these two genes significantly reduced NRF3 expression at both the mRNA and protein levels. Next, we chemically inhibited the β-catenin/TCF4 complex with iCRT14, which attenuates its DNA binding activity [27] ( Figure 2H ). As expected, iCRT14 treatment substantially reduced NRF3 mRNA levels. Collectively, these results strongly indicate that the β-catenin/TCF4 complex is a direct regulator of NRF3 gene induction in colon cancer cells.
The β-catenin/TCF4-NRF3 Axis Is Conserved in Other Cancer Cells
We also investigated β-catenin/TCF4-mediated NRF3 regulation in other human cancer cell lines: DLD-1 (colorectal adenocarcinoma), H1299 (non-small cell lung carcinoma), A172 (glioblastoma) and HeLa (cervical epithelioid carcinoma) ( Figure 3A ). All these cell lines, except for HeLa cells, harbor mutations in the Wnt-β-catenin system, resulting in constitutive β-catenin activation [28] . As such, both β-catenin and TCF4 siRNA suppressed NRF3 mRNA expression in A172 and H1299 cells but not in HeLa cells. In DLD-1 cells, β-catenin siRNA but not TCF4 siRNA caused a reduction in NRF3 expression, implying the possibility that β-catenin activates NRF3 expression through other TCF family members. Supporting these results, these cell lines, but not HeLa cells, showed nuclear β-catenin accumulation, implying that it was transcriptionally active ( Figure 3B and Supplementary Figure S1 ). Moreover, we addressed the biological relevance of the β-catenin/TCF4 complex in relation to the NRF3 homologue NRF1 ( Figure 3C ). The data revealed that β-catenin or TCF4 knockdown did not affect the expression of NRF1. These data indicate that the β-catenin/TCF4-NRF3 axis is present in other tissue-derived cancer cells that harbor mutations in the Wnt pathway. The experiment was performed as described in the legend for Figure 2. (B) Nuclear localization of β-catenin and TCF4 in cancer cells. Nuclear extracts from the indicated cells were prepared and subjected to western blot analyses. Histone H3 served as a loading control. The absence of α-Tubulin in the extracts indicates no cytoplasmic fraction contamination. (C) qRT-PCR analysis of NRF1 upon β-catenin or TCF4 knockdown in HCT116 cells. mRNA expression levels were normalized to β-actin expression, and the data are presented as the mean ± SD (n = 3). *** p < 0.005, n.s., not significant (ANOVA-Tukey in A and C).
NRF3 Activates Cell Proliferation and GLUT1 Gene Expression in Colon Cancer Cells
Our finding highlighted another question: what is the biological function of induced NRF3 in cancer cells? We previously revealed that NRF3 knockdown reduced DLD-1 cell growth [11] . Similar experiments using HCT116 cells demonstrated that NRF3 siRNA significantly reduced cell growth ( Figure 4A ). To identify direct NRF3 target genes in cancer cells, we searched ChIP sequence data for MAFF and MAFK in the ChIP-Atlas database [29] because ChIP sequence data for NRF3 were not available and because these sMaf proteins are heterodimerization partners of NRF3. Intriguingly, we discovered MAFF-and MAFK-ChIP peaks on three species-conserved AREs in the GLUT1 (SLC2A1) gene ( Figure 4B ). Because GLUT1 is well known to uptake glucose for the proliferation of glycolytic cancer cells [24, 25] , it is possible that NRF3 promotes cell proliferation by mediating GLUT1 expression. To validate this possibility, we first performed ChIP analysis to determine the recruitment of NRF3 to these ARE sites ( Figure 4C ). The results clearly demonstrated that NRF3 binds to these ARE sites in the GLUT1 gene enhancer. We next conducted siRNA knockdown ) qRT-PCR analysis of NRF1 upon β-catenin or TCF4 knockdown in HCT116 cells. mRNA expression levels were normalized to β-actin expression, and the data are presented as the mean ± SD (n = 3). *** p < 0.005, n.s., not significant (ANOVA-Tukey in (A,C)).
Our finding highlighted another question: what is the biological function of induced NRF3 in cancer cells? We previously revealed that NRF3 knockdown reduced DLD-1 cell growth [11] . Similar experiments using HCT116 cells demonstrated that NRF3 siRNA significantly reduced cell growth ( Figure 4A ). To identify direct NRF3 target genes in cancer cells, we searched ChIP sequence data for MAFF and MAFK in the ChIP-Atlas database [29] because ChIP sequence data for NRF3 were not available and because these sMaf proteins are heterodimerization partners of NRF3. Intriguingly, we discovered MAFF-and MAFK-ChIP peaks on three species-conserved AREs in the GLUT1 (SLC2A1) gene ( Figure 4B ). Because GLUT1 is well known to uptake glucose for the proliferation of glycolytic cancer cells [24, 25] , it is possible that NRF3 promotes cell proliferation by mediating GLUT1 expression. To validate this possibility, we first performed ChIP analysis to determine the recruitment of NRF3 to these ARE sites ( Figure 4C ). The results clearly demonstrated that NRF3 binds to these ARE sites in the GLUT1 gene enhancer. We next conducted siRNA knockdown experiments ( Figure 4D ). NRF3 siRNA clearly reduced GLUT1 expression at both the mRNA and protein levels. We had found that NRF3 promotes the degradation of the tumor suppressor p53 through activating the 20S proteasome [manuscript submitted by Waku et al.] . In addition, p53 is reported to downregulate GLUT1 gene expression [30] . To examine the possibility that NRF3 activates GLUT1 expression by downregulating p53, we conducted a double knockdown experiment and found negative results (Supplementary Figure S3) . We thus conclude that NRF3 leads to the upregulation of the GLUT1 gene in cancer cells. experiments ( Figure 4D ). NRF3 siRNA clearly reduced GLUT1 expression at both the mRNA and protein levels. We had found that NRF3 promotes the degradation of the tumor suppressor p53 through activating the 20S proteasome [manuscript submitted by Waku et al.] . In addition, p53 is reported to downregulate GLUT1 gene expression [30] . To examine the possibility that NRF3 activates GLUT1 expression by downregulating p53, we conducted a double knockdown experiment and found negative results (Supplementary Figure S3) . We thus conclude that NRF3 leads to the upregulation of the GLUT1 gene in cancer cells. 
(t-test). (D)
NRF3 knockdown attenuated GLUT1 gene expression at both the mRNA and protein levels. NRF3 siRNA was transfected into HCT116 cells, and GLUT1 gene expression was determined by qRT-PCR at 48 h after transfection. The arrows and arrowheads in the immunoblot indicate the cytoplasmic and nuclear forms of NRF3, respectively. RNA expression levels were normalized to β-actin expression, and data are presented as the mean ± SD (n = 3). *** p < 0.005 (t-test). RNA expression levels were normalized to β-actin expression, and data are presented as the mean ± SD (n = 3). *** p < 0.005 (t-test).
The β-catenin/Tcf4-Nrf3 Axis Is Conserved in Mouse Intestinal Tumors
To further validate our finding regarding the β-catenin/TCF4-NRF3 axis, we performed in vivo experiments using mouse intestine. Apc∆716 mice develop intestinal tumors due to a null mutation in the Apc gene, thereby activating β-catenin [31] . Upon analyzing intestinal tumors in Apc∆716 mice, we observed significant upregulation of Nrf3 expression and the β-catenin target gene c-Myc (Figure 5A 
The β-catenin/Tcf4-Nrf3 Axis is Conserved in Mouse Intestinal Tumors
To further validate our finding regarding the β-catenin/TCF4-NRF3 axis, we performed in vivo experiments using mouse intestine. ApcΔ716 mice develop intestinal tumors due to a null mutation in the Apc gene, thereby activating β-catenin [31] . Upon analyzing intestinal tumors in ApcΔ716 mice, we observed significant upregulation of Nrf3 expression and the β-catenin target gene c-Myc ( Figure  5A ). The mRNA expression of each gene was normalized to Gapdh expression, and the data are presented as the mean ± SD (n = 3). * p < 0.05, ** p < 0.01, *** p < 0.005, n.s., not significant (t-test).
We next conducted similar experiments using mouse intestine-derived organoids to eliminate nonepithelial cell contamination. Organoids are considered to recapitulate physiological tissues better than a conventional two-dimensional (2D) culture system because of their self-organizing Gene expression of the Nrf3-related factors Nrf1 and Nrf2 was not altered. Nqo1 is a target gene of Nrf2. The mRNA expression of each gene was normalized to Gapdh expression, and the data are presented as the mean ± SD (n = 3). * p < 0.05, ** p < 0.01, *** p < 0.005, n.s., not significant (t-test).
We next conducted similar experiments using mouse intestine-derived organoids to eliminate nonepithelial cell contamination. Organoids are considered to recapitulate physiological tissues better than a conventional two-dimensional (2D) culture system because of their self-organizing structures [32] [33] [34] . We generated mouse intestine-derived organoids lacking the Apc gene (KO) by infecting Apc flox/flox intestine organoids (f/f) with Cre-expressing lentivirus ( Figure 5B ). Consistent with previous reports [35, 36] , Apc deletion induced the β-catenin target genes c-Myc and Axin2 as well as the intestine epithelial stem cell markers Lgr5 and Cd44 ( Figure 5C ). Importantly, Apc KO organoids showed high induction of the Nrf3 gene. We also observed significant upregulation of the Glut1 gene as well as the Gclm and xCt genes, which are known to contain AREs, in Apc KO organoids. Alternatively, loss of Apc did not induce the expression of Nrf1, Nrf2 or its target gene Nqo1 ( Figure 5D ). Our findings suggest that the β-catenin/TCF4-NRF3 axis is conserved in mouse intestinal tumors.
Correlation of Gene Expression between NRF3 and Target Genes of The β-catenin/TCF4 Complex in a Human Cancer Database
Finally, we searched the GEPIA database to confirm the physiological relevance of the association between the Wnt-β-catenin pathway and NRF3 ( Figure 6 ). Because c-MYC and LGR5 are direct target genes of the β-catenin/TCF4 complex, the analysis showed a significant correlation among them. We thus conclude that NRF3 is induced by the β-catenin/TCF4 complex in human cancer cells. structures [32] [33] [34] . We generated mouse intestine-derived organoids lacking the Apc gene (KO) by infecting Apc flox/flox intestine organoids (f/f) with Cre-expressing lentivirus ( Figure 5B ). Consistent with previous reports [35, 36] , Apc deletion induced the β-catenin target genes c-Myc and Axin2 as well as the intestine epithelial stem cell markers Lgr5 and Cd44 ( Figure 5C ). Importantly, Apc KO organoids showed high induction of the Nrf3 gene. We also observed significant upregulation of the Glut1 gene as well as the Gclm and xCt genes, which are known to contain AREs, in Apc KO organoids. Alternatively, loss of Apc did not induce the expression of Nrf1, Nrf2 or its target gene Nqo1 ( Figure 5D ). Our findings suggest that the β-catenin/TCF4-NRF3 axis is conserved in mouse intestinal tumors.
Finally, we searched the GEPIA database to confirm the physiological relevance of the association between the Wnt-β-catenin pathway and NRF3 (Figure 6 ). Because c-MYC and LGR5 are direct target genes of the β-catenin/TCF4 complex, the analysis showed a significant correlation among them. We thus conclude that NRF3 is induced by the β-catenin/TCF4 complex in human cancer cells. 
Discussion
Our present study identified that the β-catenin/TCF4 complex in the Wnt signaling pathway activates NRF3 mRNA expression, consequently leading to the upregulation of cell proliferation and GLUT1 gene expression in cancer cells (Figure 7) . Tumors evolve by acquiring a series of sequential gene mutations that endow cells with the hallmarks of cancer, including resistance to apoptosis and self-sufficiency in growth signals [17] . The mutations that confer a selective growth advantage to the cell are called "driver" mutations. For instance, mutation of the tumor suppressor APC gene in the Wnt/β-catenin pathway is an initial and crucial event in normal epithelial cells that initiates human sporadic colorectal tumorigenesis [37] . Additionally, it has been reported that APC mutations cause global metabolic reprogramming of cells by inducing the expression of the protooncogene c-MYC, a 
Our present study identified that the β-catenin/TCF4 complex in the Wnt signaling pathway activates NRF3 mRNA expression, consequently leading to the upregulation of cell proliferation and GLUT1 gene expression in cancer cells (Figure 7) . Tumors evolve by acquiring a series of sequential gene mutations that endow cells with the hallmarks of cancer, including resistance to apoptosis and self-sufficiency in growth signals [17] . The mutations that confer a selective growth advantage to the cell are called "driver" mutations. For instance, mutation of the tumor suppressor APC gene in the Wnt/β-catenin pathway is an initial and crucial event in normal epithelial cells that initiates human sporadic colorectal tumorigenesis [37] . Additionally, it has been reported that APC mutations cause global metabolic reprogramming of cells by inducing the expression of the protooncogene c-MYC, a β-catenin target gene [21] [22] [23] . Based on these results, we surmise that NRF3 plays a physiological role in the initiation of tumorigenesis. β-catenin target gene [21] [22] [23] . Based on these results, we surmise that NRF3 plays a physiological role in the initiation of tumorigenesis. Figure 7 . Schematic model of the β-catenin/TCF4-NRF3 axis in cancer cells. APC gene deletion is a crucial first step in the initiation of human sporadic colorectal cancer [17] . This deletion activates β-catenin protein and, consequently, the TCF4-mediated expression of tumor-related genes such as the protooncogene c-MYC. This study showed that β-catenin/TCF4 also activates NRF3 mRNA expression, which leads to the upregulation of proliferation and GLUT1 gene expression in cancer cells. These results define a new biological function of the β-catenin/TCF4-NRF3 axis in cancer cells.
We recently discovered that NRF3 activates the proliferation of cancer cells by promoting the degradation of the tumor suppressor p53 through activating the 20S proteasome [11, Waku et al., under submission]. Inhibition of the tumor suppressor function of p53 is required to acquire resistance to cell death, a crucial cancer hallmark. Nevertheless, it has been reported that p53 gene mutations arise at the final step of colorectal tumor development, eventually generating malignant carcinoma ( Figure 7 ) [17] . Thus, we also consider that one biological function of NRF3 might be the suppression of p53 function before its genetic inhibition at the final stage of cancer onset.
Sustaining the stemness of intestine epithelial stem and progenitor cells is indispensable for the development of colorectal tumors [18] . To this end, the β-catenin/TCF4 complex augments the expression of stemness-related genes, such as the Axin2 and Lgr5 genes, thereby promoting the proliferation of stem/progenitor cells. Consistently, we showed that Apc deletion in mouse Apc flox/flox organoids substantially induced the expression of these genes along with the Nrf3 gene ( Figure 5C ). It is also possible that NRF3 plays biological roles in sustaining the stemness of intestine epithelial stem/progenitor cells.
It appears that β-catenin/TCF4 merely mediates the expression of NRF3 target genes by inducing NRF3 mRNA. However, NRF3 can be considered a stress-inducible transcription factor because of our following three observations: (1) Under physiological conditions, NRF3 is sequestered in the endoplasmic reticulum (ER), thereby preventing its nuclear translocation and transcriptional activity [38] . (2) The ERAD-related E3 ubiquitin ligase HRD1 promotes the cytoplasmic degradation of NRF3 [11] . (3) The nuclear translocation of NRF3 requires the proteolytic enzyme DDI2, through a similar mechanism as that of NRF1 [11] (arrow and arrowheads in Figures 2E,G and 4D ). This evidence allows us to hypothesize that certain unidentified stresses and/or signals trigger both cytoplasmic sequestration escape and nuclear entry of NRF3. This hypothetical mechanism may explain in part why Nrf3 knockout mice do not show apparent abnormalities under physiological conditions [8, 9] . Considering that APC mutations dramatically change the cell metabolic status by inducing the c-MYC gene, some metabolites or activated signal transduction pathways may activate the nuclear translocation of NRF3. For a comprehensive understanding of the physiological function of NRF3 in cancer cells, the identification of intrinsic NRF3 activation and/or stress signals remains a crucial issue.
We found that the glucose transporter GLUT1 is a candidate NRF3 target gene in colon cancer cells. This finding is reasonable because cancer cells dramatically change their metabolic status from oxidative phosphorylation to glycolysis by activating c-MYC, a β-catenin target gene [21] . We need to explore whether NRF3-mediated GLUT1 expression confers glucose uptake and proliferation Figure 7 . Schematic model of the β-catenin/TCF4-NRF3 axis in cancer cells. APC gene deletion is a crucial first step in the initiation of human sporadic colorectal cancer [17] . This deletion activates β-catenin protein and, consequently, the TCF4-mediated expression of tumor-related genes such as the protooncogene c-MYC. This study showed that β-catenin/TCF4 also activates NRF3 mRNA expression, which leads to the upregulation of proliferation and GLUT1 gene expression in cancer cells. These results define a new biological function of the β-catenin/TCF4-NRF3 axis in cancer cells.
We recently discovered that NRF3 activates the proliferation of cancer cells by promoting the degradation of the tumor suppressor p53 through activating the 20S proteasome [11] (Waku et al., under submission). Inhibition of the tumor suppressor function of p53 is required to acquire resistance to cell death, a crucial cancer hallmark. Nevertheless, it has been reported that p53 gene mutations arise at the final step of colorectal tumor development, eventually generating malignant carcinoma ( Figure 7 ) [17] . Thus, we also consider that one biological function of NRF3 might be the suppression of p53 function before its genetic inhibition at the final stage of cancer onset.
It appears that β-catenin/TCF4 merely mediates the expression of NRF3 target genes by inducing NRF3 mRNA. However, NRF3 can be considered a stress-inducible transcription factor because of our following three observations: (1) Under physiological conditions, NRF3 is sequestered in the endoplasmic reticulum (ER), thereby preventing its nuclear translocation and transcriptional activity [38] . (2) The ERAD-related E3 ubiquitin ligase HRD1 promotes the cytoplasmic degradation of NRF3 [11] . (3) The nuclear translocation of NRF3 requires the proteolytic enzyme DDI2, through a similar mechanism as that of NRF1 [11] (arrow and arrowheads in Figure 2E ,G and Figure 4D ). This evidence allows us to hypothesize that certain unidentified stresses and/or signals trigger both cytoplasmic sequestration escape and nuclear entry of NRF3. This hypothetical mechanism may explain in part why Nrf3 knockout mice do not show apparent abnormalities under physiological conditions [8, 9] . Considering that APC mutations dramatically change the cell metabolic status by inducing the c-MYC gene, some metabolites or activated signal transduction pathways may activate the nuclear translocation of NRF3. For a comprehensive understanding of the physiological function of NRF3 in cancer cells, the identification of intrinsic NRF3 activation and/or stress signals remains a crucial issue.
We found that the glucose transporter GLUT1 is a candidate NRF3 target gene in colon cancer cells. This finding is reasonable because cancer cells dramatically change their metabolic status from oxidative phosphorylation to glycolysis by activating c-MYC, a β-catenin target gene [21] . We need to explore whether NRF3-mediated GLUT1 expression confers glucose uptake and proliferation abilities to cancer cells. Unfortunately, we could not show that GLUT1 knockdown reduces glucose uptake by HCT116 cells (data not shown). Because GLUT3 mRNA is also induced in an NRF3-independent mechanism in cancer cells [24, 25] , GLUT3 might compensate for the loss of GLUT1 function. Further examination is required to determine the effects of NRF3-mediated GLUT1 gene expression on cancer cells.
Materials and Methods
Reagents and Antibodies
iCRT14 was purchased from Sigma-Aldrich (SML0203) (St. Louis, MO, USA). The antibodies utilized were anti-β-catenin (610153; BD Biosciences, San Jose, CA, USA), anti-TCF4 (C48H11; Cell Signaling Technology, Danvers, MA, USA), anti-α-Tubulin (DM1A; Sigma-Aldrich, St. Louis, MO, USA), and anti-histone H3 (06-755; Millipore, Billerica, MA, USA). Normal mouse IgG (Santa Cruz Biotechnology, Dallas, TX, USA) and normal rabbit IgG (Wako Pure Chemicals, Osaka, Japan) were used for chromatin immunoprecipitation analysis. A monoclonal NRF3 antibody (#9408) raised against human NRF3 (amino acids 364-415) was generated as described previously [11] .
RNA Dot Blot Analysis
The Human Multiple Tissue Expression (MTE TM ) Array, which contains dots of polyA + RNA normalized to ubiquitin from 76 different human tissues, was purchased from Clontech (7775-1; Lot #8110216, Palo Alto, CA, USA). A radiolabeled probe was prepared from the 500-bp HindIII fragment of the human clone SKhNrf3/1-1 [4] . Hybridization was performed according to the manufacturer's instructions.
EGF, Y-27632 and L-glutamine (Thermo Fisher Scientific Inc. Rockford, IL, USA) in a humidified incubator at 5% CO 2 and 37 • C.
Transfection
The transfection of short interfering RNA (siRNA) was performed using RNAiMAX (Thermo Fisher Scientific Inc. Rockford, IL, USA) according to the manufacturer's protocols. Sequences of siRNAs targeting human mRNAs are listed in Table S1 .
RNA Extraction and Quantitative Real-Time PCR (qRT-PCR)
Total RNA was prepared using ISOGENII (Nippon Gene, Tokyo, Japan). One microgram of total RNA was utilized for cDNA synthesis using random hexamer primers (Takara Bio, Ohtsu, Japan) and Moloney murine leukemia virus (M-MLV) reverse transcriptase (Thermo Fisher Scientific Inc. Rockford, IL, USA). qRT-PCR was conducted using SYBR Premix Ex Taq II (Takara Bio, Ohtsu, Japan) and a Thermal Cycler Dice Real Time System II (Takara Bio, Ohtsu, Japan). The PCR conditions were 95 • C for 30 sec, 30 cycles of 95 • C for 5 sec, 60 • C for 30 sec and 95 • C for 15 sec, 60 • C for 30 sec and 95 • C for 15 sec. All target gene expression levels were normalized to β-actin or Gapdh expression. The sequences of the primers used are listed in Table S2 .
Cell Fractionation and Western Blot Analysis
To prepare whole cell extracts, cells were lysed with SDS sample buffer (50 mM Tris-HCl (pH 6.8), 10% glycerol and 1% SDS). For nuclear extracts, cells were lysed in buffer A (10 mM Tris-HCl (pH 8.0), 10 mM KCl, 0.1 mM EDTA, 1.5 mM MgCl 2 ), 1x protease inhibitor (Nacalai Tesque, Kyoto, Japan), 10 µM MG132 (Peptide Institute, Osaka, Japan) and 10% NP-40 (final concentration 2%). After centrifugation, the precipitated nuclei were lysed with SDS sample buffer. The protein concentrations of the cell extracts were measured using a bicinchoninic acid (BCA) kit (Thermo Fisher Scientific Inc. Rockford, IL, USA). Proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to PVDF membranes (Immobilon-P transfer membrane, Millipore, Billerica, MA, USA). The blots were incubated with the primary antibodies indicated on the figures and then with a horseradish peroxidase-conjugated secondary antibody (Thermo Fisher Scientific Inc. Rockford, IL, USA). The protein bands were visualized using enhanced chemiluminescence (GE Healthcare, Pittsburgh, PA, USA).
Chromatin Immunoprecipitation (ChIP)
HCT116 cells grown on a 10-cm dish were cross-linked in 1% formaldehyde for 10 min, followed by quenching with 0.125 M glycine for 5 min at room temperature and two washes with ice-cold phosphate-buffered saline (PBS). ChIP analysis was conducted as described previously [40] , with minor modifications as follows: immunoprecipitated DNA was purified by phenol-chloroform extraction and ethanol precipitation, dissolved in TE and analyzed by quantitative real-time PCR. The utilized antibodies were anti-NRF3 (#9408), anti-β-catenin (610153; BD Biosciences, San Jose, CA, USA) and anti-TCF4 (C48H11; Cell Signaling Technology, Danvers, MA, USA). Melting curves of qRT-PCR show the specificity of the reaction (Supplementary Figure S2) . The sequences of the primers used are listed in Table S2 .
Cell Proliferation Assay
HCT116 cells were plated onto 6-well dishes (1 × 10 5 cells per well), transfected with the indicated siRNA and cultured for the indicated number of days. The cells were detached from plates with 0.05% trypsin and gently suspended in ice-cold PBS. Cell counting was performed using a hemocytometer.
